Bernstein SocGen Group Upgrades Ionis Pharmaceuticals (IONS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
June 17, 2024 6:21 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $70.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS)
The analyst comments "We hosted IONSs CEO and CFO for Boston/Baltimore NDR and the meetings strengthen our conviction that IONS is poised to successfully... More
